Hempalta Corp. (CVE:HEMP – Get Free Report) Director Darren Hartley Bondar purchased 310,474 shares of the business’s stock in a transaction dated Tuesday, December 24th. The shares were purchased at an average price of C$0.05 per share, for a total transaction of C$14,499.14.
Darren Hartley Bondar also recently made the following trade(s):
- On Tuesday, November 5th, Darren Hartley Bondar acquired 200,000 shares of Hempalta stock. The shares were purchased at an average price of C$0.04 per share, for a total transaction of C$8,000.00.
- On Monday, October 14th, Darren Hartley Bondar purchased 135,000 shares of Hempalta stock. The shares were acquired at an average price of C$0.04 per share, for a total transaction of C$5,400.00.
Hempalta Price Performance
Shares of Hempalta stock opened at C$0.04 on Friday. The company has a current ratio of 3.99, a quick ratio of 0.88 and a debt-to-equity ratio of 28.72. Hempalta Corp. has a 1 year low of C$0.04 and a 1 year high of C$0.30. The stock has a 50-day moving average price of C$0.04 and a 200 day moving average price of C$0.10. The company has a market cap of C$3.80 million, a P/E ratio of -0.32 and a beta of -0.10.
Hempalta Company Profile
Hempalta Corp., an agricultural cleantech company, produces and processes industrial hemp in North America. It manufactures products using a process known as HempTrain that enables to produce a range of hemp-based commercial and consumer products. The company also engages in the hemp carbon credit market.
Recommended Stories
- Five stocks we like better than Hempalta
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Top 3 Investment Themes to Watch for in 2025
- What to Know About Investing in Penny Stocks
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- What is a buyback in stocks? A comprehensive guide for investors
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Hempalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hempalta and related companies with MarketBeat.com's FREE daily email newsletter.